The rise, fall, and resurgence of immunotherapy in type 1 diabetes

Moufida Ben Nasr, Francesca D'Addio, Vera Usuelli, Sara Tezza, Reza Abdi, Paolo Fiorina

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Despite considerable effort to halt or delay destruction of β-cells in autoimmune type 1 diabetes (T1D), success remains elusive. Over the last decade, we have seen a proliferation of knowledge on the pathogenesis of T1D that emerged from studies performed in non-obese diabetic (NOD) mice. However, while results of these preclinical studies appeared to hold great promise and boosted patients' hopes, none of these approaches, once tested in clinical settings, induced remission of autoimmune diabetes in individuals with T1D. The primary obstacles to translation reside in the differences between the human and murine autoimmune responses and in the contribution of many environmental factors associated with the onset of disease. Moreover, inaccurate dosing as well as inappropriate timing and uncertain length of drug exposure have played a central role in the negative outcomes of such therapeutic interventions. In this review, we summarize the most important approaches tested thus far in T1D, beginning with the most successful preclinical studies in NOD mice and ending with the latest disappointing clinical trials in humans. Finally, we highlight recent stem cell-based trials, for which expectations in the scientific community and among individuals with T1D are high.

Original languageEnglish
Pages (from-to)31-38
Number of pages8
JournalPharmacological Research
Volume98
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Type 1 Diabetes Mellitus
Immunotherapy
Inbred NOD Mouse
Autoimmunity
Stem Cells
Clinical Trials
Pharmaceutical Preparations

Keywords

  • B cells
  • Hematopoietic stem cells
  • Immunosuppression
  • Immunotherapy
  • NOD mice
  • T cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Pharmacology

Cite this

The rise, fall, and resurgence of immunotherapy in type 1 diabetes. / Ben Nasr, Moufida; D'Addio, Francesca; Usuelli, Vera; Tezza, Sara; Abdi, Reza; Fiorina, Paolo.

In: Pharmacological Research, Vol. 98, 01.08.2015, p. 31-38.

Research output: Contribution to journalArticle

Ben Nasr, Moufida ; D'Addio, Francesca ; Usuelli, Vera ; Tezza, Sara ; Abdi, Reza ; Fiorina, Paolo. / The rise, fall, and resurgence of immunotherapy in type 1 diabetes. In: Pharmacological Research. 2015 ; Vol. 98. pp. 31-38.
@article{337bb35655f54acbadcb79ce34e4a0fe,
title = "The rise, fall, and resurgence of immunotherapy in type 1 diabetes",
abstract = "Despite considerable effort to halt or delay destruction of β-cells in autoimmune type 1 diabetes (T1D), success remains elusive. Over the last decade, we have seen a proliferation of knowledge on the pathogenesis of T1D that emerged from studies performed in non-obese diabetic (NOD) mice. However, while results of these preclinical studies appeared to hold great promise and boosted patients' hopes, none of these approaches, once tested in clinical settings, induced remission of autoimmune diabetes in individuals with T1D. The primary obstacles to translation reside in the differences between the human and murine autoimmune responses and in the contribution of many environmental factors associated with the onset of disease. Moreover, inaccurate dosing as well as inappropriate timing and uncertain length of drug exposure have played a central role in the negative outcomes of such therapeutic interventions. In this review, we summarize the most important approaches tested thus far in T1D, beginning with the most successful preclinical studies in NOD mice and ending with the latest disappointing clinical trials in humans. Finally, we highlight recent stem cell-based trials, for which expectations in the scientific community and among individuals with T1D are high.",
keywords = "B cells, Hematopoietic stem cells, Immunosuppression, Immunotherapy, NOD mice, T cells, Type 1 diabetes",
author = "{Ben Nasr}, Moufida and Francesca D'Addio and Vera Usuelli and Sara Tezza and Reza Abdi and Paolo Fiorina",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.phrs.2014.07.004",
language = "English",
volume = "98",
pages = "31--38",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - The rise, fall, and resurgence of immunotherapy in type 1 diabetes

AU - Ben Nasr, Moufida

AU - D'Addio, Francesca

AU - Usuelli, Vera

AU - Tezza, Sara

AU - Abdi, Reza

AU - Fiorina, Paolo

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Despite considerable effort to halt or delay destruction of β-cells in autoimmune type 1 diabetes (T1D), success remains elusive. Over the last decade, we have seen a proliferation of knowledge on the pathogenesis of T1D that emerged from studies performed in non-obese diabetic (NOD) mice. However, while results of these preclinical studies appeared to hold great promise and boosted patients' hopes, none of these approaches, once tested in clinical settings, induced remission of autoimmune diabetes in individuals with T1D. The primary obstacles to translation reside in the differences between the human and murine autoimmune responses and in the contribution of many environmental factors associated with the onset of disease. Moreover, inaccurate dosing as well as inappropriate timing and uncertain length of drug exposure have played a central role in the negative outcomes of such therapeutic interventions. In this review, we summarize the most important approaches tested thus far in T1D, beginning with the most successful preclinical studies in NOD mice and ending with the latest disappointing clinical trials in humans. Finally, we highlight recent stem cell-based trials, for which expectations in the scientific community and among individuals with T1D are high.

AB - Despite considerable effort to halt or delay destruction of β-cells in autoimmune type 1 diabetes (T1D), success remains elusive. Over the last decade, we have seen a proliferation of knowledge on the pathogenesis of T1D that emerged from studies performed in non-obese diabetic (NOD) mice. However, while results of these preclinical studies appeared to hold great promise and boosted patients' hopes, none of these approaches, once tested in clinical settings, induced remission of autoimmune diabetes in individuals with T1D. The primary obstacles to translation reside in the differences between the human and murine autoimmune responses and in the contribution of many environmental factors associated with the onset of disease. Moreover, inaccurate dosing as well as inappropriate timing and uncertain length of drug exposure have played a central role in the negative outcomes of such therapeutic interventions. In this review, we summarize the most important approaches tested thus far in T1D, beginning with the most successful preclinical studies in NOD mice and ending with the latest disappointing clinical trials in humans. Finally, we highlight recent stem cell-based trials, for which expectations in the scientific community and among individuals with T1D are high.

KW - B cells

KW - Hematopoietic stem cells

KW - Immunosuppression

KW - Immunotherapy

KW - NOD mice

KW - T cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84930763863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930763863&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2014.07.004

DO - 10.1016/j.phrs.2014.07.004

M3 - Article

VL - 98

SP - 31

EP - 38

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -